OptimizeRx Projects Q4 Revenue $31.1M, EPS $0.09; Q3 Beat by 9.4%
OptimizeRx forecasts Q4 2025 revenue of $31.10 million and EPS of $0.09, with full-year 2025 revenue estimated at $108.18 million and EPS of $0.05. Q3 revenue beat by 9.4% to $26.07 million and EPS topped estimates by $0.14 per share.
1. Forecast Overview
OptimizeRx is set to report Q4 2025 earnings on March 5, with revenue expected at $31.10 million and EPS of $0.09. Full-year 2025 figures are forecasted at $108.18 million in revenue and $0.05 in EPS, reflecting steady growth projections.
2. Quarterly Performance
In Q3 2025, OptimizeRx delivered $26.07 million in revenue, surpassing the $23.83 million consensus by 9.4%, and achieved EPS of $0.04 versus a negative $0.10 estimate. Despite the beat, the stock declined sharply following the release.
3. Estimate Trends
Revenue estimates for full-year 2025 have remained at $108.18 million, while 2026 projections hold at $120.00 million. Earnings forecasts are steady at $0.05 per share for 2025 and $0.20 per share for 2026 over the past 90 days.
4. Analyst Price Targets
Analysts set a one-year average price target of $24.33, ranging from $17.00 to $32.00, implying over 230% upside. The consensus brokerage recommendation stands at 1.9, indicating an Outperform rating.